Literature DB >> 20535143

An evolving role for immunotherapy in metastatic RCC.

Riccardo Autorino, Giuseppe Di Lorenzo.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20535143     DOI： 10.1038/nrurol.2010.64

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Authors:  Martin E Gore; Clare L Griffin; Barry Hancock; Poulam M Patel; Lynda Pyle; Michael Aitchison; Nicholas James; Roderick T D Oliver; Jozef Mardiak; Tahera Hussain; Richard Sylvester; Mahesh K B Parmar; Patrick Royston; Peter F A Mulders
Journal:  Lancet       Date:  2010-02-10       Impact factor: 79.321

2.  Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.

Authors:  S Négrier; A Caty; T Lesimple; J Y Douillard; B Escudier; J F Rossi; P Viens; F Gomez
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

3.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

4.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

5.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

Authors:  Bernard Escudier; Cezary Szczylik; Thomas E Hutson; Tomasz Demkow; Michael Staehler; Frédéric Rolland; Sylvie Negrier; Nicole Laferriere; Urban J Scheuring; David Cella; Sonalee Shah; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

6.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

Review 7.  Treatment selection for patients with metastatic renal cell carcinoma.

Authors:  Michael B Atkins; Toni K Choueiri; Daniel Cho; Meredith Regan; Sabina Signoretti
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

8.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

Review 9.  Metastatic renal cell carcinoma: recent advances in the targeted therapy era.

Authors:  Giuseppe Di Lorenzo; Riccardo Autorino; Cora N Sternberg
Journal:  Eur Urol       Date:  2009-09-08       Impact factor: 20.096

10.  IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.

Authors:  J Atzpodien; H Kirchner; H J Illiger; B Metzner; D Ukena; H Schott; P J Funke; M Gramatzki; S Jürgenson; T Wandert; T Patzelt; M Reitz
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.